<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1529779</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Impact of the Naples Prognostic Score at admission on long-term prognosis among patients with coronary artery disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wang</surname>
<given-names>Bo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/921030/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Chen</surname>
<given-names>Wan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Shi</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Pei</surname>
<given-names>Mingyu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhou</surname>
<given-names>Yao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2671201/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Yanlin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2831323/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Yutao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qiu</surname>
<given-names>Guozheng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duan</surname>
<given-names>Wenlong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Shengxin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Xiangrong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Zhongyuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ji</surname>
<given-names>Qingwei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1794986/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lyu</surname>
<given-names>Liwen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2875107/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Emergency Medicine, Research Center of Cardiovascular Disease, The People&#x2019;s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences</institution>, <addr-line>Nanning</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Cardiology, Research Center of Cardiovascular Disease, The People&#x2019;s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences</institution>, <addr-line>Nanning</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Di Wang, Jilin Agriculture University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Jiale Zhang, China Science and Technology Development Center for Chinese Medicine, China</p>
<p>Bart&#x142;omiej K. So&#x142;tysik, Medical University of Lodz, Poland</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Liwen Lyu, <email xlink:href="mailto:iculvliwen@163.com">iculvliwen@163.com</email>; Qingwei Ji, <email xlink:href="mailto:jqw124@163.com">jqw124@163.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1529779</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>11</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>05</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Wang, Chen, Shi, Pei, Zhou, Wei, Tang, Qiu, Duan, Chen, Chen, Zhang, Shi, Ji and Lyu</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Wang, Chen, Shi, Pei, Zhou, Wei, Tang, Qiu, Duan, Chen, Chen, Zhang, Shi, Ji and Lyu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>The Naples Prognostic Score (NPS) is innovatively constructed to comprehensively evaluate the inflammatory and nutritional status according to several basic blood examinations. This study aimed to investigate the correlation between NPS and long-term prognosis in patients with coronary artery disease (CAD).</p>
</sec>
<sec>
<title>Methods</title>
<p>The analysis data of this retrospective cohort study were collected from electronic health records in the People&#x2019;s Hospital of Guangxi Zhuang Autonomous Region. All adult patients who underwent coronary angiology (CAG) and were diagnosed as having CAD at the People&#x2019;s Hospital of Guangxi Zhuang Autonomous Region from March 2013 to December 2023 were enrolled. The primary endpoint was all-cause death during follow-up.</p>
</sec>
<sec>
<title>Results</title>
<p>The 28,799 patients were divided into three groups according to the NPS value, with 803 (2.79%) in group 0, 12,130 (42.12%) in group 1, and 15,866 (55.09%) in group 2. Over the median follow-up period of 6.12 years, 3,630 patients (12.60%) died. Long-term all-cause mortality was significantly higher in group 2 and group 1 compared with group 0 (log-rank <italic>p</italic> &lt; 0.001). Cox regression analysis showed that both continuous NPS and categorical NPS groups were significantly associated with the risk of all-cause mortality in patients with CAD [per 1-point decrement: full adjusted HR = 1.15; 95% CI, 1.11&#x2013;1.19; compared with group 0 (NPS of 0), group 1 (NPS of 1 or 2), full adjusted HR = 1.38, 95% CI: 1.03&#x2013;1.85, and group 2 (NPS of 3 or 4), full adjusted HR = 1.70, 95% CI: 1.27&#x2013;2.28]. Restricted cubic spline analyses showed a linear relationship between NPS and risk of long-term all-cause death.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>The present study demonstrates that the NPS was independently associated with long-term all-cause mortality among patients with CAD.</p>
</sec>
</abstract>
<kwd-group>
<kwd>coronary artery disease</kwd>
<kwd>Naples Prognostic Score</kwd>
<kwd>long-term prognosis</kwd>
<kwd>mortality</kwd>
<kwd>inflammatory and nutritional status</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="42"/>
<page-count count="9"/>
<word-count count="3583"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Nutritional Immunology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>The high prevalence and mortality rate caused by coronary artery disease (CAD) pose a serious public health challenge worldwide (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). The identification of modifiable risk factors is crucial for implementing interventions on these variables to lower the risk of poor long-term prognosis. Previous studies reported that malnutrition and high inflammation status played important roles in the poor prognosis of patients with CAD (<xref ref-type="bibr" rid="B3">3</xref>&#x2013;<xref ref-type="bibr" rid="B5">5</xref>). The immune and nutritional status was increasingly determined as a substantial prognostic risk factor in patients with CAD, independent of traditional CAD risk factors (<xref ref-type="bibr" rid="B6">6</xref>), whereas most validated predictors were just solitary inflammatory or nutrition-related markers, which caused the evaluations to become incomprehensive.</p>
<p>The Naples Prognostic Score (NPS) is innovatively constructed to comprehensively evaluate the inflammatory and nutritional status according to several basic blood examinations. It has been demonstrated that NPS is correlated to prognosis in various diseases (<xref ref-type="bibr" rid="B7">7</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). However, no studies verified the association between NPS and long-term outcomes in patients with CAD.</p>
<p>Accordingly, this research intended to explore the prognostic significance of baseline NPS at admission, aiming to offer a simple and reliable approach to identify high-risk individuals among the CAD population.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2_1">
<title>Study design and data collection</title>
<p>A total of 39,653 individuals who underwent coronary angiography (CAG) for proven CAD at the People&#x2019;s Hospital of Guangxi Zhuang Autonomous Region during March 2013 and December 2023 were enrolled. This research adopted a retrospective cohort design. A retrospective cohort design was used in this study. The following clinical characteristics were collected from electronic health records (EHRs): demographic characteristics, laboratory examination, and medication at discharge. The final database was cross-validated across multiple sources (e.g., laboratory systems and billing records) to minimize inconsistencies. Follow-up information was obtained and preserved by trained researchers. The study was approved by the Ethics Committee of Guangxi Zhuang Autonomous Region People&#x2019;s Hospital and conducted following the Declaration of Helsinki (IRB No. KY-QT-202103).</p>
<p>Patients fulfilling the following criteria were excluded: (1) individuals aged less than 18 years; (2) individuals with a history of myocardial infarction; (3) individuals who had undergone percutaneous coronary intervention (PCI) previously; (4) individuals who had undergone coronary artery bypass grafting previously; (5) individuals diagnosed with cancer; (6) individuals lacking follow-up information; and (7) individuals lacking albumin, total cholesterol, neutrophil, lymphocyte, monocyte, or triglyceride examination results. <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref> shows the flowchart of this study.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Study flowchart.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1529779-g001.tif"/>
</fig>
</sec>
<sec id="s2_2">
<title>Clinical definitions</title>
<p>The primary outcome of this study was the all-cause mortality. The diagnosis of CAD was derived from angiographic confirmation (&gt;50% stenosis in one vessel at the lowest), which was derived from structured EHR data (e.g., procedural reports and cardiologist notes). To assess NPS value, the following four variables were applied: serum albumin concentrations, total cholesterol concentrations, neutrophil-to-lymphocyte ratio (NLR) levels, and lymphocyte-to-monocyte ratio (LMR) levels (<xref ref-type="bibr" rid="B6">6</xref>). According to previous reports, serum albumin &#x2265;40 g/L, total cholesterol &gt; 180 mg/dL (2.03 mmol/L), LMR &gt; 4.44, or NLR &#x2264; 2.96 was scored as 0, while serum albumin &lt;40 g/L, total cholesterol &#x2264; 180&#x2013; mg/dL (2.03 mmol/L), LMR &#x2264; 4.44, or NLR &gt; 2.96 was scored as 1. NPS is the sum of the scores of each of the four factors. To convert total cholesterol from mmol/L to mg/dL, multiply by 88.6. Details were reported in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>. All procedures for PCI as well as CAG followed the clinical standard guidelines (<xref ref-type="bibr" rid="B10">10</xref>&#x2013;<xref ref-type="bibr" rid="B12">12</xref>). A variety of concomitant diseases were taken into consideration, including acute myocardial infarction (AMI), congestive heart failure (CHF), hypertension, diabetes mellitus, chronic kidney disease (CKD), anemia, chronic obstructive pulmonary disease (COPD), and stroke. CHF was defined as New York Heart Association (NYHA) class &gt;2 or Killip class &gt;1 (<xref ref-type="bibr" rid="B13">13</xref>). CKD was determined as estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m<sup>2</sup> (<xref ref-type="bibr" rid="B14">14</xref>). The level of eGFR was calculated based on the Modification of Diet in Renal Disease (MDRD) formula (<xref ref-type="bibr" rid="B15">15</xref>). Other comorbidities were derived from ICD codes plus clinician diagnosis.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Calculation of the Naples Prognostic Score (NPS).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Components</th>
<th valign="top" align="left">Cutoff value</th>
<th valign="top" align="left">Points</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" rowspan="2">Albumin</td>
<td valign="top" align="left">&#x2265;40 g/L</td>
<td valign="top" align="left">0</td>
</tr>
<tr>
<td valign="top" align="left">&lt;40 g/L</td>
<td valign="top" align="left">1</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="2">Total cholesterol</td>
<td valign="top" align="left">&gt;180 mg/dL (2.03 mmol/L)</td>
<td valign="top" align="left">0</td>
</tr>
<tr>
<td valign="top" align="left">&#x2264;180 mg/dL (2.03 mmol/L)</td>
<td valign="top" align="left">1</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="2">LMR</td>
<td valign="top" align="left">&gt;4.44</td>
<td valign="top" align="left">0</td>
</tr>
<tr>
<td valign="top" align="left">&#x2264;4.44</td>
<td valign="top" align="left">1</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="2">NLR</td>
<td valign="top" align="left">&gt;2.96</td>
<td valign="top" align="left">1</td>
</tr>
<tr>
<td valign="top" align="left">&#x2264;2.96</td>
<td valign="top" align="left">0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s2_3">
<title>Statistical analysis</title>
<p>Based on the final score, study population was categorized into 3 groups (group 0: NPS value of 0; group 1: NPS value of 1 or 2; group 2: NPS value of 3 or 4) (<xref ref-type="bibr" rid="B6">6</xref>). This research compared continuous variables using the Wilcoxon rank sum test or Student&#x2019;s <italic>t</italic> test and expressed them as mean with median with interquartile range (IQR) or standard deviation (SD). For categorical variables, the chi-square test was applied and number and percentage (%) were reported. The Kaplan&#x2013;Meier curves were applied to estimate the effect of different groups on long-term all-cause mortality. To determine and quantify the magnitude of risk, univariate and multivariate COX regression were conducted. The study carefully selected covariates to create four models: (1) univariate; (2) adjusted age and gender; (3) adjusted age, gender, PCI and morbidities; and (4) adjusted all covariates above as well as medication use of renin&#x2013;angiotensin system inhibitor (RASi), statins, and &#x3b2;-blocker. The same covariates were used in restricted cubic spline (RCS) analyses to investigate potential nonlinear correlations. R software (version 3.6.3) was used for all statistical analyses. A <italic>p</italic>-value of less than 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Patient characteristics</title>
<p>Study participants were 28,799 patients (mean age 63.10 &#xb1; 10.56 years, 74.75% men) suffering from CAD (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). Of these patients, 803 (2.79%) were classified as group 0, 12,130 (42.12%) were classified as group 1, and 15,866 (55.09%) were classified as group 2. There were 21,148 (73.43%) patients who underwent PCI, 5,795 (20.12%) had AMI, 2,260 (7.86%) had CHF, 16,268 (56.49%) had hypertension, 7,595 (26.37%) had diabetes mellitus, 5,757 (20.89%) had CKD, 248 (0.86%) had COPD, and 1,568 (5.44%) had stroke.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Baseline characteristics of the study population.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="left">Characteristics*</th>
<th valign="bottom" align="left">Overall</th>
<th valign="bottom" align="left">Group 0</th>
<th valign="bottom" align="left">Group 1</th>
<th valign="bottom" align="left">Group 2</th>
<th valign="middle" rowspan="2" align="left">
<italic>P</italic> value</th>
</tr>
<tr>
<th valign="bottom" align="left">(<italic>N</italic> = 28,799)</th>
<th valign="bottom" align="left">(<italic>N</italic> = 803)</th>
<th valign="bottom" align="left">(<italic>N</italic> = 12,130)</th>
<th valign="bottom" align="left">(<italic>N</italic> = 15,866)</th>
</tr>
</thead>
<tbody>
<tr>
<th valign="top" colspan="6" align="left">Demographic</th>
</tr>
<tr>
<td valign="middle" align="left">Age, years</td>
<td valign="top" align="left">63.10 (10.56)</td>
<td valign="top" align="left">58.78 (9.66)</td>
<td valign="top" align="left">61.56 (10.31)</td>
<td valign="top" align="left">64.50 (10.57)</td>
<td valign="bottom" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">Male, <italic>n</italic> (%)</td>
<td valign="top" align="left">21,526 (74.75)</td>
<td valign="top" align="left">468 (58.28)</td>
<td valign="top" align="left">8,376 (69.05)</td>
<td valign="top" align="left">12,682 (79.93)</td>
<td valign="bottom" align="left">&lt;0.001</td>
</tr>
<tr>
<th valign="middle" colspan="6" align="left">Medical history</th>
</tr>
<tr>
<td valign="middle" align="left">AMI, <italic>n</italic> (%)</td>
<td valign="top" align="left">5,795 (20.12)</td>
<td valign="top" align="left">35 (4.36)</td>
<td valign="top" align="left">1,422 (11.72)</td>
<td valign="top" align="left">4,338 (27.34)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">CHF, <italic>n</italic> (%)</td>
<td valign="top" align="left">2,260 (7.86)</td>
<td valign="top" align="left">29 (3.61)</td>
<td valign="top" align="left">639 (5.27)</td>
<td valign="top" align="left">1,592 (10.05)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">Hypertension, <italic>n</italic> (%)</td>
<td valign="top" align="left">16,268 (56.49)</td>
<td valign="top" align="left">428 (53.30)</td>
<td valign="top" align="left">6,631 (54.67)</td>
<td valign="top" align="left">9,209 (58.04)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">Diabetes mellitus, <italic>n</italic> (%)</td>
<td valign="top" align="left">7,595 (26.37)</td>
<td valign="top" align="left">210 (26.15)</td>
<td valign="top" align="left">3,122 (25.74)</td>
<td valign="top" align="left">4,263 (26.87)</td>
<td valign="top" align="left">0.10</td>
</tr>
<tr>
<td valign="middle" align="left">CKD, <italic>n</italic> (%)</td>
<td valign="top" align="left">5,757 (20.89)</td>
<td valign="top" align="left">81 (10.64)</td>
<td valign="top" align="left">1,853 (16.08)</td>
<td valign="top" align="left">3,823 (25.03)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">COPD, <italic>n</italic> (%)</td>
<td valign="top" align="left">248 (0.86)</td>
<td valign="top" align="left">3 (0.37)</td>
<td valign="top" align="left">77 (0.63)</td>
<td valign="top" align="left">168 (1.06)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">Stroke, <italic>n</italic> (%)</td>
<td valign="top" align="left">1,568 (5.44)</td>
<td valign="top" align="left">18 (2.24)</td>
<td valign="top" align="left">511 (4.21)</td>
<td valign="top" align="left">1,039 (6.55)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">PCI, <italic>n</italic> (%)</td>
<td valign="top" align="left">21,148 (73.43)</td>
<td valign="top" align="left">525 (65.38)</td>
<td valign="top" align="left">8,565 (70.61)</td>
<td valign="top" align="left">12,058 (76.00)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<th valign="middle" colspan="6" align="left">Laboratory examination</th>
</tr>
<tr>
<td valign="bottom" align="left">Albumin, g/L</td>
<td valign="top" align="left">36.05 (4.04)</td>
<td valign="top" align="left">42.19 (1.79)</td>
<td valign="top" align="left">37.46 (3.69)</td>
<td valign="top" align="left">34.66 (3.69)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="bottom" align="left">Total cholesterol, mmol/L</td>
<td valign="top" align="left">4.54 (1.09)</td>
<td valign="top" align="left">5.75 (0.80)</td>
<td valign="top" align="left">4.99 (1.06)</td>
<td valign="top" align="left">4.13 (0.94)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="bottom" align="left">HDL-C, mmol/L</td>
<td valign="top" align="left">1.00 (0.26)</td>
<td valign="top" align="left">1.16 (0.28)</td>
<td valign="top" align="left">1.05 (0.27)</td>
<td valign="top" align="left">0.96 (0.25)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="bottom" align="left">LDL-C, mmol/L</td>
<td valign="top" align="left">2.77 (0.92)</td>
<td valign="top" align="left">3.57 (0.85)</td>
<td valign="top" align="left">3.09 (0.93)</td>
<td valign="top" align="left">2.49 (0.80)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="bottom" align="left">Triglyceride, mmol/L</td>
<td valign="top" align="left">1.63 (1.08)</td>
<td valign="top" align="left">2.29 (1.78)</td>
<td valign="top" align="left">1.82 (1.22)</td>
<td valign="top" align="left">1.44 (0.85)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="bottom" align="left">Neutrophil, 109/L</td>
<td valign="top" align="left">4.99 (2.06)</td>
<td valign="top" align="left">3.93 (1.12)</td>
<td valign="top" align="left">4.24 (1.48)</td>
<td valign="top" align="left">5.62 (2.26)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="bottom" align="left">Lymphocyte, 109/L</td>
<td valign="top" align="left">1.93 (0.66)</td>
<td valign="top" align="left">2.54 (0.63)</td>
<td valign="top" align="left">2.22 (0.63)</td>
<td valign="top" align="left">1.68 (0.57)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="bottom" align="left">Monocyte, 109/L</td>
<td valign="top" align="left">0.62 (0.23)</td>
<td valign="top" align="left">0.46 (0.14)</td>
<td valign="top" align="left">0.56 (0.20)</td>
<td valign="top" align="left">0.68 (0.23)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">NLR</td>
<td valign="top" align="left">2.99 (1.97)</td>
<td valign="top" align="left">1.59 (0.49)</td>
<td valign="top" align="left">2.02 (0.98)</td>
<td valign="top" align="left">3.79 (2.20)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">LMR</td>
<td valign="top" align="left">3.44 (1.70)</td>
<td valign="top" align="left">5.77 (1.67)</td>
<td valign="top" align="left">4.34 (1.81)</td>
<td valign="top" align="left">2.64 (1.04)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<th valign="bottom" colspan="6" align="left">Medication</th>
</tr>
<tr>
<td valign="bottom" align="left">RASi, <italic>n</italic> (%)</td>
<td valign="top" align="left">14,417 (50.86)</td>
<td valign="top" align="left">330 (41.30)</td>
<td valign="top" align="left">5,978 (49.84)</td>
<td valign="top" align="left">8,109 (52.15)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="bottom" align="left">&#x3b2;-blocker, <italic>n</italic> (%)</td>
<td valign="top" align="left">22,812 (80.48)</td>
<td valign="top" align="left">639 (79.97)</td>
<td valign="top" align="left">9,628 (80.27)</td>
<td valign="top" align="left">12,545 (80.68)</td>
<td valign="top" align="left">0.65</td>
</tr>
<tr>
<td valign="bottom" align="left">Statin, <italic>n</italic> (%)</td>
<td valign="top" align="left">26,814 (94.60)</td>
<td valign="top" align="left">753 (94.24)</td>
<td valign="top" align="left">11,306 (94.26)</td>
<td valign="top" align="left">14,755 (94.89)</td>
<td valign="top" align="left">0.06</td>
</tr>
<tr>
<th valign="bottom" colspan="6" align="left">Clinical outcome</th>
</tr>
<tr>
<td valign="bottom" align="left">All-cause mortality</td>
<td valign="top" align="left">3,630 (12.60)</td>
<td valign="top" align="left">51 (6.35)</td>
<td valign="top" align="left">1,218 (10.04)</td>
<td valign="top" align="left">2,361 (14.88)</td>
<td valign="top" align="left">&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AMI, acute myocardial infarction; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; RASi, renin&#x2013;angiotensin system inhibitor.</p>
</fn>
<fn>
<p>*Data are presented as the mean value (standard deviation) or number of participants (percentage).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Patients in groups 2 and 1 were older on average compared to group 0. Moreover, the prevalence of comorbid conditions such as AMI, CHF, hypertension, CKD, COPD, and stroke was also higher in group 2 and group 1 than in group 0. For laboratory examination, the concentrations of albumin, total cholesterol, HDL-C, LDL-C, triglyceride, lymphocyte, and LMR were lower in groups 2 and 1. Meanwhile, neutrophil, monocyte, and NLR were higher in groups 2 and 1.</p>
</sec>
<sec id="s3_2">
<title>Primary outcomes</title>
<p>During the median follow-up period of 6.12 years, 3,630 patients (12.60%) died. Of these, 51 (6.35%), 1,218 (10.04%), and 2,361 (14.88%) were in groups 0, 1, and 2, respectively. On the basis of Kaplan&#x2013;Meier cumulative hazard curves shown in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>, a significantly higher cumulative incidence was determined from group 2 (log-rank <italic>p</italic> &lt; 0.001) versus group 0 and group 1. In <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>, results of Cox regression are shown. When NPS value was analyzed as a continuous variable, per 1-point increasement was related to 15% increased risk (adjusted HR, 1.15; 95% CI, 1.11&#x2013;1.19). When NPS value was analyzed as a categorical variable, patients in group 2 (NPS of 3 or 4) and group 1 (NPS of 1 or 2) have a 70% and 38% increased risk compared to group 0 (NPS of 0) patients with low levels.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Cumulative incidence of all-cause death for three NPS groups.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1529779-g002.tif"/>
</fig>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Cox proportion hazard model stratified by NPS group for all-cause mortality.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="center">Model</th>
<th valign="middle" colspan="2" align="center">Model 1</th>
<th valign="middle" colspan="2" align="center">Model 2</th>
<th valign="middle" colspan="2" align="center">Model 3</th>
<th valign="middle" colspan="2" align="center">Model 4</th>
</tr>
<tr>
<th valign="middle" align="center">HR (95% CI)</th>
<th valign="middle" align="center">
<italic>p</italic>-value</th>
<th valign="middle" align="center">HR (95% CI)</th>
<th valign="middle" align="center">
<italic>p</italic>-value</th>
<th valign="middle" align="center">HR (95% CI)</th>
<th valign="middle" align="center">
<italic>p</italic>-value</th>
<th valign="middle" align="center">HR (95% CI)</th>
<th valign="middle" align="center">
<italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<th valign="middle" colspan="9" align="left">NPS was analyzed as a continuous variable</th>
</tr>
<tr>
<td valign="middle" align="left">Per 1-point increment</td>
<td valign="middle" align="center">1.29 (1.24&#x2013;1.33)</td>
<td valign="middle" align="center">&lt;0.001</td>
<td valign="middle" align="center">1.21 (1.16&#x2013;1.25)</td>
<td valign="middle" align="center">&lt;0.001</td>
<td valign="middle" align="center">1.16 (1.11&#x2013;1.20)</td>
<td valign="middle" align="center">&lt;0.001</td>
<td valign="middle" align="center">1.15 (1.11&#x2013;1.19)</td>
<td valign="middle" align="center">&lt;0.001</td>
</tr>
<tr>
<th valign="middle" colspan="9" align="left">NPS was analyzed as a categorical variable</th>
</tr>
<tr>
<td valign="middle" align="left">Group 1 (0)</td>
<td valign="middle" align="center">Ref</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">Ref</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">Ref</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">Ref</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="left">Group 2 (1&#x2013;2)</td>
<td valign="middle" align="center">1.53 (1.16&#x2013;2.03)</td>
<td valign="middle" align="center">0.003</td>
<td valign="middle" align="center">1.37 (1.03&#x2013;1.81)</td>
<td valign="middle" align="center">0.03</td>
<td valign="middle" align="center">1.34 (1.01&#x2013;1.79)</td>
<td valign="middle" align="center">0.04</td>
<td valign="middle" align="center">1.38 (1.03&#x2013;1.85)</td>
<td valign="middle" align="center">0.03</td>
</tr>
<tr>
<td valign="middle" align="left">Group 3 (3&#x2013;4)</td>
<td valign="middle" align="center">2.30 (1.74&#x2013;3.03)</td>
<td valign="middle" align="center">&lt;0.001</td>
<td valign="middle" align="center">1.84 (1.39&#x2013;2.43)</td>
<td valign="middle" align="center">&lt;0.001</td>
<td valign="middle" align="center">1.68 (1.26&#x2013;2.25)</td>
<td valign="middle" align="center">&lt;0.001</td>
<td valign="middle" align="center">1.70 (1.27&#x2013;2.28)</td>
<td valign="middle" align="center">&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>NPS, Naples Prognostic Score.</p>
</fn>
<fn>
<p>Model 1: unadjusted.</p>
</fn>
<fn>
<p>Model 2: adjusted age and gender.</p>
</fn>
<fn>
<p>Model 3: adjusted age, gender, PCI, and morbidities including AMI, CHF, hypertension, diabetes mellitus, CKD, COPD, and stroke.</p>
</fn>
<fn>
<p>Model 4: adjusted all covariates above and medication use of RASi, statins, and &#x3b2;-blocker.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In order to examine the existing potential nonlinear correlation, RCS analysis was conducted with the same covariates form four Cox models (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). The result illustrated positive linear correlation between NPS and risk of outcome (all <italic>p</italic> for nonlinear &gt; 0.05, <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Restricted cubic splines of the NPS and hazard ratio for mortality. <bold>(A)</bold> The restrict spline curve of the univariate Cox model. <bold>(B)</bold> The restrict spline curve of multivariate Cox model 2, adjusted age and gender. <bold>(C)</bold> The restrict spline curve of multivariate Cox model 3, adjusted age, gender, PCI, and morbidities including AMI, CHF, hypertension, diabetes mellitus, CKD, COPD, and stroke. <bold>(D)</bold> The restrict spline curve of multivariate Cox model 4, adjusted all covariates above and medication use of RASi, statins, and &#x3b2;-blocker.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1529779-g003.tif"/>
</fig>
</sec>
<sec id="s3_3">
<title>Subgroup analysis</title>
<p>Subgroup analyses generally agreed with main analysis results (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). There was a significant interaction effect for gender (<italic>p</italic> for interaction = 0.006). Among female individuals, the results were even more dramatic.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Subgroup analysis.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1529779-g004.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>This cohort study of participants with CAD examined the association between NPS value and risk of all-cause death. The result clearly demonstrated a linear positive correlation between NPS and the risk of long-term all-cause death, with each point increase in NPS increasing the risk by 15% in CAD population. Additionally, patients in the high NPS value group had a poorer prognosis compared to the group with an NPS value of 0. After adjustment of all confounders, the results were still robust. According to further subgroup analysis, most results were consistent.</p>
<p>The NPS is a newly detected scoring system that can comprehensively evaluate the individual&#x2019;s immunological and nutritional status according to several basic blood examinations. These easily accessible and routinely tested indicators included albumin level, total cholesterol concentration, lymphocyte, neutrophil, and monocyte. NPS was initially constructed and verified as an independent prognostic risk factor in colorectal cancer (<xref ref-type="bibr" rid="B6">6</xref>). Subsequently, the NPS&#x2019;s ability to predict prognosis was validated in various diseases, and increased NPS levels were found to be independently correlated to increased risk of poor prognosis (<xref ref-type="bibr" rid="B7">7</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). Erdogan et&#xa0;al.&#x2019;s study, which included 1,887 consecutive patients with STEMI who were undergoing PCI, reported that the high-NPS group had a higher rate of death compared to the low-NPS group (19.1% vs 7.8%, <italic>p</italic> &lt; 0.001) (<xref ref-type="bibr" rid="B16">16</xref>). After adjusting confounders, evaluated NPS was associated with poorer prognosis and high NPS (3&#x2013;4) increased the risk 1.49-fold. In Saygi et&#xa0;al.&#x2019;s study that recruited 3,828 patients with STEMI with emergency PCI, the result illustrated that the rate of in-hospital death was elevated in the high-NPS group in contrast to the medium- and low-NPS group (<xref ref-type="bibr" rid="B17">17</xref>). Multivariable logistic regression also showed that the high- and medium-NPS group significantly increased the risk of in-hospital death.</p>
<p>NPS encompasses not only immunoinflammatory markers like NLR and LMR, but also total cholesterol and serum albumin. These indicators mirrored an individual&#x2019;s nutritional status and inflammation level. As a result, the body condition of the patient could be evaluated in a more comprehensive and efficient manner. According to the NPS scoring system, high NPS levels most likely presented underlying low albumin, low total cholesterol, low LMR, and high NLR, suggesting malnutrition and high inflammation status. The significance of inflammation in initiating, promoting, and destabilizing atherosclerotic plaques is paramount (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>). Systemic inflammation was commonly related to vascular wall inflammation (<xref ref-type="bibr" rid="B20">20</xref>). Several clinical studies demonstrated that taking anti-inflammatory drugs, such as therapeutic monoclonal antibodies against IL-1&#x3b2; (canakinumab) and colchicine is useful in modulating inflammation, reducing adverse events risk and improving the prognosis of chronic CAD (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). A growing body of research has suggested that inflammation-related indexes, such as LMR and NLR, are related to CAD severity and prognosis (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). NLR and LMR are straightforward and economically efficient biomarkers that mirror the complex equilibrium between innate and adaptive immune responses (<xref ref-type="bibr" rid="B25">25</xref>).</p>
<p>Notably, NLR has been demonstrated to be a reliable biomarker of inflammation in the vascular wall, and it is readily accessible (<xref ref-type="bibr" rid="B26">26</xref>). Through reactive oxygen species, cytokines, proteases, and neutrophil extracellular traps, neutrophils were known to adversely affect chronic inflammatory disorders in individuals with increased NLR (<xref ref-type="bibr" rid="B27">27</xref>). LMR is another inflammatory indicator calculated based on lymphocytes and monocytes. Decreased LMR was related to the poor prognosis. Inflammatory cell infiltration is an important mechanism of atherosclerosis (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B28">28</xref>). Lymphocytes and monocytes played crucial roles in atherosclerosis&#x2019; early stage; meanwhile, neutrophils were involved in plaque destabilization and thrombosis (<xref ref-type="bibr" rid="B29">29</xref>).</p>
<p>Furthermore, nutrition, being a modifiable element, had a further impact on the prognosis of patients with CAD. Malnutrition, in particular, significantly affects prognosis. Several studies have identified malnutrition as the most prevalent cause of secondary immunologic disorders. Low serum total cholesterol levels and albumin concentrations were important objective indicators of malnutrition. Previous research has demonstrated that a low total cholesterol level serves as a biological indicator for concurrent cachexia, malnutrition, cancer, and other chronic diseases, which have confirmed detrimental effects for prognosis (<xref ref-type="bibr" rid="B30">30</xref>). Additionally, there is emerging evidence suggesting that cholesterol levels were clearly associated with regulation of immune cell function. Decreased cholesterol levels result in diminished activation of immune signaling and reduced antitumor activity (<xref ref-type="bibr" rid="B31">31</xref>). Serum albumin concentrations were linked to both nutritional status and the acute phase reaction, as well as chronic inflammatory diseases (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>). Existing studies indicated that decreased albumin concentrations might serve as an indicator of sustained arterial injury and advancement of thrombosis as well as atherosclerosis (<xref ref-type="bibr" rid="B34">34</xref>). As a result of decreased albumin concentrations, catabolic cytokines were produced, muscle breakdown occurred, and appetite was suppressed (<xref ref-type="bibr" rid="B33">33</xref>). Given the established roles of neutrophils, monocytes, lymphocytes, serum albumin, and total cholesterol in the poor prognosis of patients with CAD, NPS emerges as a promising tool. NPS calculated by combining these factors not only is less susceptible to various non-pathological factors than individual indicators, but also captures the patient&#x2019;s inflammatory and nutritional status, which are crucial in the prognosis of patients with CAD. Our study validated the association between NPS and poor prognosis in patients with CAD using large sample data, and found a linear correlation between NPS level and the risk of poor prognosis. This may make NPS a good prognostic assessment tool for patients with CAD. It enables clinicians to identify high-risk patients at an early stage. However, precisely because NPS is a comprehensive assessment of nutritional status and inflammation levels, timely clinical interventions targeting high-risk patients need to be further explored.</p>
<p>According to the results of subgroup analysis, the association between NPS and long-term all-cause death was more significant in female patients (<italic>p</italic> for interaction = 0.006). The value of HR was also higher in female patients. There may be several possible explanations. Firstly, women passed through adverse metabolic disturbances and lipid profile deterioration more than men (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). A previous study conducted in humans and mice confirmed that estrogen preserves endothelial function (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>). Thus, because of older age at onset and decreased estrogen levels, endothelial dysfunction is more severe in female patients with CAD than in male patients. The above factors together resulted in a worse nutritional status and higher levels of inflammation played more important roles in female patients&#x2019; prognosis. Secondly, women tend to present later CAD than men and suffered more from chronic comorbidities. Several present studies including Steg et&#xa0;al.&#x2019;s CLARIFY study and Chen et&#xa0;al.&#x2019;s study demonstrated this (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>). Furthermore, the clinical presentation was more atypical in women, and female patients received fewer interventions and drug therapies (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). NPS may provide additional clues apart from the control of comorbidities such as hypertension, CHF, and CKD to improve prognosis in female patients with CAD.</p>
<p>It is necessary to admit that there existed several certain limitations. Firstly, although this research was derived from a single-center retrospective cohort, the enrolled patients originated from the largest cardiac intervention center in the Guangxi Zhuang Autonomous Region, which rendered the sample representative and ensured the study&#x2019;s quality control. Secondly, the generalization of our results is restricted to the Chinese population without taking into account other races. Thirdly, this study only evaluated the baseline admission NPS levels and did not assess the effect of NPS changes during follow-up. This should be further investigated. Fourthly, there were limited data on the included patients, without information about body mass index (BMI), smoking status, and socioeconomic factors. This may partially affect the results. However, we adjusted for potential confounders whenever possible and constructed three multivariate Cox regression models to ensure the robustness of the results.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusion</title>
<p>This research indicated the significance of inflammation and nutritional status in case of an unfavorable prognosis. Based on routine examination, NPS can comprehensively evaluate the prognosis of patients with CAD. There was a linear positive correlation between NPS value and prognosis.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The datasets presented in this article are not readily available because it is not applicable at this stage. The datasets analyzed during the current study will be available from the corresponding author on reasonable request when the study is finished. Requests to access the datasets should be directed to LL <email xlink:href="mailto:iculvliwen@163.com">iculvliwen@163.com</email>.</p>
</sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Research Ethics Committee of Guangxi Zhuang Autonomous Region People&#x2019;s Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants&#x2019; legal guardians/next of kin because all traceable personal identifiers were removed from the analytic dataset to protect patients&#x2019; privacy. For this reason, the requirement for informed consent was waived, which was approved by the Research Ethics Committee of Guangxi Zhuang Autonomous Region People&#x2019;s Hospital (No. KY-QT-202103).</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>BW: Conceptualization, Writing &#x2013; original draft. WC: Conceptualization, Writing &#x2013; original draft. LS: Writing &#x2013; original draft. MP: Writing &#x2013; original draft. YZ: Writing &#x2013; original draft. YW: Writing &#x2013; original draft. YT: Writing &#x2013; original draft. GQ: Writing &#x2013; original draft. WD: Writing &#x2013; original draft. SC: Project administration, Writing &#x2013; original draft. XC: Project administration, Writing &#x2013; original draft. ZZ: Writing &#x2013; original draft. YS: Project administration, Writing &#x2013; original draft. QJ: Writing &#x2013; review &amp; editing. LL: Writing &#x2013; review &amp; editing.</p>
</sec>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Guangxi Natural Science Foundation (2023GXNSFBA026088, 2023GXNSFBA026036, 2023GXNSFAA026059, 2024GXNSFAA010012 and 2025GXNSFAA069574), the Guangxi Science and Technology Program (GKAB25069064, GKAB24010174 and GKAB23026019), the Guangxi Medical and Health Appropriate Technology Research and Development Project (S2020076, S2020080, S2022015, S2022025 and S2023011), Guangxi Science and Technology Base and Special Talents' Project (GKAD17129026) and the Guangxi Self-funded Research project (Z20200743 and Z-A20220030).</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We thank Home for Researchers editorial team (<ext-link ext-link-type="uri" xlink:href="http://www.home-for-researchers.com">www.home-for-researchers.com</ext-link>).</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<collab>GBD 2017 Causes of Death Collaborators</collab>
</person-group>. <article-title>Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title>. <source>Lancet</source>. (<year>2018</year>) <volume>39210159</volume>:<page-range>1736&#x2013;88</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0140-6736(18)32203-7</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Mensah</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>CO</given-names>
</name>
<name>
<surname>Addolorato</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ammirati</surname> <given-names>E</given-names>
</name>
<name>
<surname>Baddour</surname> <given-names>LM</given-names>
</name>
<etal/>
</person-group>. <article-title>Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study</article-title>. <source>J Am Coll Cardiol</source>. (<year>2020</year>) <volume>7625</volume>:<fpage>2982</fpage>&#x2013;<lpage>3021</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2020.11.010</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ying</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>G</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Malnutrition affects cholesterol paradox in coronary artery disease: a 41,229 Chinese cohort study</article-title>. <source>Lipids Health Dis</source>. (<year>2021</year>) <volume>201</volume>:<fpage>36</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12944-021-01460-6</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raposeiras Roub&#xed;n</surname> <given-names>S</given-names>
</name>
<name>
<surname>Abu Assi</surname> <given-names>E</given-names>
</name>
<name>
<surname>Cesp&#xf3;n Fernandez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Barreiro Pardal</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lizancos Castro</surname> <given-names>A</given-names>
</name>
<name>
<surname>Parada</surname> <given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevalence and prognostic significance of malnutrition in patients with acute coronary syndrome</article-title>. <source>J Am Coll Cardiol</source>. (<year>2020</year>) <volume>767</volume>:<page-range>828&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2020.06.058</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>A synergistic association between inflammation, malnutrition, and mortality in patients with diabetics</article-title>. <source>Front Nutr</source>. (<year>2022</year>) <volume>9</volume>:<elocation-id>872512</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fnut.2022.872512</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galizia</surname> <given-names>G</given-names>
</name>
<name>
<surname>Lieto</surname> <given-names>E</given-names>
</name>
<name>
<surname>Auricchio</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cardella</surname> <given-names>F</given-names>
</name>
<name>
<surname>Mabilia</surname> <given-names>A</given-names>
</name>
<name>
<surname>Podzemny</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Naples prognostic score, based on nutritional and inflammatory status, is an independent predictor of long-term outcome in patients undergoing surgery for colorectal cancer</article-title>. <source>Dis Colon Rectum</source>. (<year>2017</year>) <volume>6012</volume>:<page-range>1273&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/dcr.0000000000000961</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic significance of preoperative Naples prognostic score on short- and long-term outcomes after pancreatoduodenectomy for ampullary carcinoma</article-title>. <source>Hepatobil Surg Nutr</source>. (<year>2021</year>) <volume>106</volume>:<page-range>825&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/hbsn-20-741</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>ZY</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>ZD</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>ZK</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>ZC</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>ZJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic value of the Naples prognostic score in patients with intrahepatic cholangiocarcinoma after hepatectomy</article-title>. <source>BMC Cancer</source>. (<year>2024</year>) <volume>241</volume>:<fpage>727</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12885-024-12502-4</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Cao C Naples prognostic score as a novel prognostic prediction indicator in adult asthma patients: A population-based study</article-title>. <source>World Allergy Organ J</source>. (<year>2023</year>) <volume>1610</volume>:<elocation-id>100825</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.waojou.2023.100825</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jneid</surname> <given-names>H</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Wright</surname> <given-names>RS</given-names>
</name>
<name>
<surname>Adams</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Bridges</surname> <given-names>CR</given-names>
</name>
<name>
<surname>Casey</surname> <given-names>DE</given-names>
<suffix>Jr.</suffix>
</name>
<etal/>
</person-group>. <article-title>2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source>. (<year>2012</year>) <volume>607</volume>:<page-range>645&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2012.06.004</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname> <given-names>GN</given-names>
</name>
<name>
<surname>Bates</surname> <given-names>ER</given-names>
</name>
<name>
<surname>Blankenship</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Bailey</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Bittl</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Cercek</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. (<year>2016</year>) <volume>6710</volume>:<page-range>1235&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2015.10.005</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byrne</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Rossello</surname> <given-names>X</given-names>
</name>
<name>
<surname>Coughlan</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Barbato</surname> <given-names>E</given-names>
</name>
<name>
<surname>Berry</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chieffo</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>2023 ESC Guidelines for the management of acute coronary syndromes</article-title>. <source>Eur Heart J</source>. (<year>2023</year>) <volume>4438</volume>:<page-range>3720&#x2013;826</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/eurheartj/ehad191</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehran</surname> <given-names>R</given-names>
</name>
<name>
<surname>Aymong</surname> <given-names>ED</given-names>
</name>
<name>
<surname>Nikolsky</surname> <given-names>E</given-names>
</name>
<name>
<surname>Lasic</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Iakovou</surname> <given-names>I</given-names>
</name>
<name>
<surname>Fahy</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation</article-title>. <source>J Am Coll Cardiol</source>. (<year>2004</year>) <volume>447</volume>:<page-range>1393&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2004.06.068</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<collab>National Kidney Foundation</collab>
</person-group>. <article-title>K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification</article-title>. <source>Am J Kidney Dis</source>. (<year>2002</year>) <volume>392 Suppl 1</volume>:<fpage>S1</fpage>&#x2013;<lpage>266</lpage>. Available online at: <uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/11904577/">https://pubmed.ncbi.nlm.nih.gov/11904577/</uri>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manjunath</surname> <given-names>G</given-names>
</name>
<name>
<surname>Tighiouart</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ibrahim</surname> <given-names>H</given-names>
</name>
<name>
<surname>MacLeod</surname> <given-names>B</given-names>
</name>
<name>
<surname>Salem</surname> <given-names>DN</given-names>
</name>
<name>
<surname>Griffith</surname> <given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community</article-title>. <source>J Am Coll Cardiol</source>. (<year>2003</year>) <volume>411</volume>:<fpage>47</fpage>&#x2013;<lpage>55</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0735-1097(02)02663-3</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erdogan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Genc</surname> <given-names>O</given-names>
</name>
<name>
<surname>Ozkan</surname> <given-names>E</given-names>
</name>
<name>
<surname>Goksu</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Ibisoglu</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bilen</surname> <given-names>MN</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of naples prognostic score at admission on in-hospital and follow-up outcomes among patients with ST-segment elevation myocardial infarction</article-title>. <source>Angiology</source>. (<year>2023</year>) <volume>7410</volume>:<page-range>970&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/00033197231151559</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saygi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tanalp</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Tezen</surname> <given-names>O</given-names>
</name>
<name>
<surname>Pay</surname> <given-names>L</given-names>
</name>
<name>
<surname>Dogan</surname> <given-names>R</given-names>
</name>
<name>
<surname>Uzman</surname> <given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>The prognostic importance of the Naples prognostic score for in-hospital mortality in patients with ST-segment elevation myocardial infarction</article-title>. <source>Coron Artery Dis</source>. (<year>2024</year>) <volume>351</volume>:<page-range>31&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/mca.0000000000001285</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borghini</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mercuri</surname> <given-names>A</given-names>
</name>
<name>
<surname>Andreassi</surname> <given-names>MG</given-names>
</name>
</person-group>. <article-title>Neutrophil-to-lymphocyte, platelet-to-lymphocyte ratios, and systemic immune-inflammation index as predictors of mortality in coronary artery disease</article-title>. <source>J Cardiovasc Transl Res</source>. (<year>2023</year>) <volume>162</volume>:<page-range>473&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12265-022-10312-2</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammation and platelet hyperresponsiveness in coronary artery disease and the influence of Talin-1/&#x3b1;IIb&#x3b2;3-mediated bidirectional signaling pathway</article-title>. <source>Front Pharmacol</source>. (<year>2025</year>) <volume>16</volume>:<elocation-id>1535182</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2025.1535182</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Libby</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Inflammation in atherosclerosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2012</year>) <volume>329</volume>:<page-range>2045&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.108.179705</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ridker</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Everett</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Thuren</surname> <given-names>T</given-names>
</name>
<name>
<surname>MacFadyen</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>WH</given-names>
</name>
<name>
<surname>Ballantyne</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title>. <source>N Engl J Med</source>. (<year>2017</year>) <volume>37712</volume>:<page-range>1119&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nidorf</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Fiolet</surname> <given-names>ATL</given-names>
</name>
<name>
<surname>Mosterd</surname> <given-names>A</given-names>
</name>
<name>
<surname>Eikelboom</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Schut</surname> <given-names>A</given-names>
</name>
<name>
<surname>Opstal</surname> <given-names>TSJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Colchicine in patients with chronic coronary disease</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>38319</volume>:<page-range>1838&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa2021372</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Zhu J Neutrophil-to-lymphocyte ratio as a predictor of all-cause and cardiovascular mortality in coronary heart disease and hypertensive patients: a retrospective cohort study</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1442165</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2024.1442165</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Si</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shan</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Han</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of lymphocyte-to-monocyte ratio with total coronary plaque burden in patients with coronary artery disease</article-title>. <source>Coron Artery Dis</source>. (<year>2020</year>) <volume>317</volume>:<page-range>650&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/mca.0000000000000857</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lian</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Cheng X the neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with the severity of autoimmune encephalitis</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>911779</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.911779</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Afari</surname> <given-names>ME</given-names>
</name>
</person-group>. <article-title>Bhat T Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update</article-title>. <source>Expert Rev Cardiovasc Ther</source>. (<year>2016</year>) <volume>145</volume>:<page-range>573&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1586/14779072.2016.1154788</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jorch</surname> <given-names>SK</given-names>
</name>
</person-group>. <article-title>Kubes P An emerging role for neutrophil extracellular traps in noninfectious disease</article-title>. <source>Nat Med</source>. (<year>2017</year>) <volume>233</volume>:<page-range>279&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm.4294</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Libby</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ridker</surname> <given-names>PM</given-names>
</name>
</person-group>. <article-title>Hansson GK Inflammation in atherosclerosis: from pathophysiology to practice</article-title>. <source>J Am Coll Cardiol</source>. (<year>2009</year>) <volume>5423</volume>:<page-range>2129&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2009.09.009</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yayan</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Emerging families of biomarkers for coronary artery disease: inflammatory mediators</article-title>. <source>Vasc Health Risk Manag</source>. (<year>2013</year>) <volume>9</volume>:<page-range>435&#x2013;56</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/vhrm.S45704</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakagomi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Seino</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Noma</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kohashi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kosugi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kato</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationships between the serum cholesterol levels, production of monocyte proinflammatory cytokines and long-term prognosis in patients with chronic heart failure</article-title>. <source>Intern Med</source>. (<year>2014</year>) <volume>5321</volume>:<page-range>2415&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2169/internalmedicine.53.2672</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism</article-title>. <source>Nature</source>. (<year>2016</year>) <volume>5317596</volume>:<page-range>651&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature17412</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>YL</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>WL</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>SJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Association between preoperative nutritional status and clinical outcomes of patients with coronary artery disease undergoing percutaneous coronary intervention</article-title>. <source>Nutrients</source>. (<year>2020</year>) <volume>125</volume>:<fpage>1295</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/nu12051295</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merker</surname> <given-names>M</given-names>
</name>
<name>
<surname>Felder</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gueissaz</surname> <given-names>L</given-names>
</name>
<name>
<surname>Bolliger</surname> <given-names>R</given-names>
</name>
<name>
<surname>Tribolet</surname> <given-names>P</given-names>
</name>
<name>
<surname>K&#xe4;gi-Braun</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of baseline inflammation with effectiveness of nutritional support among patients with disease-related malnutrition: A secondary analysis of a randomized clinical trial</article-title>. <source>JAMA netw Open</source>. (<year>2020</year>) <volume>33</volume>:<elocation-id>e200663</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.0663</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuller</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Eichner</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Orchard</surname> <given-names>TJ</given-names>
</name>
<name>
<surname>Grandits</surname> <given-names>GA</given-names>
</name>
<name>
<surname>McCallum</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Tracy RP The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial</article-title>. <source>Am J Epidemiol</source>. (<year>1991</year>) <volume>13411</volume>:<page-range>1266&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a116030</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname> <given-names>T</given-names>
</name>
<name>
<surname>Fernandez</surname> <given-names>C</given-names>
</name>
<name>
<surname>Barshop</surname> <given-names>R</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Krousel-Wood</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Sex differences in cardiovascular risk profile from childhood to midlife between individuals who did and did not develop diabetes at follow-up: the bogalusa heart study</article-title>. <source>Diabetes Care</source>. (<year>2019</year>) <volume>424</volume>:<page-range>635&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/dc18-2029</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Logue</surname> <given-names>J</given-names>
</name>
<name>
<surname>Walker</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Colhoun</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Leese</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Lindsay</surname> <given-names>RS</given-names>
</name>
<name>
<surname>McKnight</surname> <given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Do men develop type 2 diabetes at lower body mass indices than women</article-title>? <source>Diabetologia</source>. (<year>2011</year>) <volume>5412</volume>:<page-range>3003&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00125-011-2313-3</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sotnikova</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bacova</surname> <given-names>B</given-names>
</name>
<name>
<surname>Vlkovicova</surname> <given-names>J</given-names>
</name>
<name>
<surname>Navarova</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tribulova</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Sex differences in endothelial function of aged hypertriglyceridemic rats - effect of atorvastatin treatment</article-title>. <source>Interdiscip Toxicol</source>. (<year>2012</year>) <volume>53</volume>:<page-range>155&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2478/v10102-012-0025-2</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paradisi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Steinberg</surname> <given-names>HO</given-names>
</name>
<name>
<surname>Hempfling</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cronin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hook</surname> <given-names>G</given-names>
</name>
<name>
<surname>Shepard</surname> <given-names>MK</given-names>
</name>
<etal/>
</person-group>. <article-title>Polycystic ovary syndrome is associated with endothelial dysfunction</article-title>. <source>Circulation</source>. (<year>2001</year>) <volume>10310</volume>:<page-range>1410&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/01.cir.103.10.1410</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steg</surname> <given-names>PG</given-names>
</name>
<name>
<surname>Greenlaw</surname> <given-names>N</given-names>
</name>
<name>
<surname>Tardif</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Tendera</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ford</surname> <given-names>I</given-names>
</name>
<name>
<surname>K&#xe4;&#xe4;b</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry</article-title>. <source>Eur Heart J</source>. (<year>2012</year>) <volume>3322</volume>:<page-range>2831&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/eurheartj/ehs289</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>SQ</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>ZD</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>HZ</given-names>
</name>
<etal/>
</person-group>. <article-title>Sex differences in characteristics, treatments, and in-hospital outcomes of patients undergoing coronary angiography or intervention</article-title>. <source>Front Cardiovasc Med</source>. (<year>2022</year>) <volume>9</volume>:<elocation-id>878566</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcvm.2022.878566</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Bilige</surname> <given-names>W</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Schulz</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Characteristics of high cardiovascular risk in 1.7 million Chinese adults</article-title>. <source>Ann Intern Med</source>. (<year>2019</year>) <volume>1705</volume>:<fpage>298</fpage>&#x2013;<lpage>308</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.7326/m18-1932</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moran</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>D</given-names>
</name>
<name>
<surname>Coxson</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>YC</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>CS</given-names>
</name>
<etal/>
</person-group>. <article-title>Future cardiovascular disease in China: markov model and risk factor scenario projections from the coronary heart disease policy model-China</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. (<year>2010</year>) <volume>33</volume>:<page-range>243&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/circoutcomes.109.910711</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>